

Curriculum Vitae
Deborah Gardner Nixon, MD

Practice Address: Dermatology Specialists of Charlotte
8936 Blakeney Professional Drive
Charlotte, NC 28277
Deborah.nixon@dscmd.com

Site Affiliation: DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

1995-1998	Residency in Dermatology
1997-1998	Chief Administrative Resident University of South Florida Medical Center Tampa, Florida
1993-1995	Residency in Internal Medicine Georgetown University Medical Center Washington, DC
1992-1993	Internship in Internal Medicine Vanderbilt University Medical Center Nashville, Tennessee
1988-1992	Doctor of Medicine University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina
1984-1988	Bachelor of Science in Zoology Duke University Durham, North Carolina

Professional Experience:

2006-Present	Dermatologist/Owner Dermatology Specialists of Charlotte
2000-2006	Dermatologist Carolina Dermatology
1998-2000	Dermatologist The Dermatology Group, PA

Licensure/Certifications:

- 1998-Present Dermatology Board Certified – State of North Carolina
- 1995-2005 Internal Medicine Board Certified– State of North Carolina

Curriculum Vitae
Deborah Gardner Nixon, MD

Professional Memberships:

1995-Present	Fellow of the American Academy of Dermatology
2003-Present	Fellow of the American Society of Dermatologic Surgeons
1998-Present	North Carolina Dermatology Association
1999-Present	Mecklenburg County Medical Society


Clinical Research:

Sub-Investigator – Abbvie Protocol M15-554: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) –SELECT – PsA 2 (2017)

Principal Investigator – Cutanea Life Sciences, Inc Protocol CLS006-CO-PR-002: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

Principal Investigator – Vanda Protocol VP-VLY-686-3101: A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis. 2019

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.



Signature

2/7/19

Date